Navigation Links
Martek Announces Final Judgment and Order of Dismissal in Class Action
Date:4/7/2008

COLUMBIA, Md., April 7, 2008 /PRNewswire-FirstCall/ -- Martek Biosciences Corporation announced today that the United States District Court for the District of Maryland has entered a Final Judgment and Order of Dismissal approving the settlement of the consolidated class action brought on behalf of certain purchasers of Martek common stock. That class action was brought under the federal securities laws and arose out of allegations, among other things, of violations of Section 10(b) and 20(a) of the Securities Exchange Act of 1934.

As previously noted in the Company's press release of December 10, 2007, the settlement of the class action calls for a cash payment of $6 million into a settlement fund, all of which has been paid by the Company's insurer. Under the terms of the Final Judgment and Order of Dismissal, that settlement fund will be distributed to class members and all claims against the Company and its past and present officers and directors named as defendants have now been dismissed.

Martek Biosciences Corporation (Nasdaq: MATK) is a leader in the innovation and development of DHA omega-3 products that promote health and wellness through every stage of life. The company produces life'sDHA, a sustainable and vegetarian source of the omega-3 fatty acid DHA (docosahexaenoic acid), for use in foods, beverages, infant formula, and supplements. The company also produces life'sARA(TM) (arachidonic acid), an omega-6 fatty acid, from a sustainable, vegetarian source, for use in infant formula. For more information on Martek Biosciences Corporation, visit http://www.martek.com/.

Sections of this release contain forward-looking statements. These statements are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors set forth in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's Form 10-K for the fiscal year ended October 31, 2007 and other filed reports on Form 10-K, Form 10-K/A, Form 10-Q and Form 8-K.

Contact:

Cassie France-Kelly

Public Relations, Martek

(443) 542-2116

media@martek.com

Kyle Stults

Investor Relations, Martek

(410) 740-0081

investors@martek.com


'/>"/>
SOURCE Martek Biosciences Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Martek to Announce Third Quarter 2007 Results on September 5, 2007
2. Martek to Present at Upcoming UBS Conference
3. Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott
4. Martek Announces Settlement of OmegaTech Milestone Litigation
5. Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge
6. European Patent Office Upholds Martek European DHA Food Patent; Scope of Original Claims Narrowed
7. Martek to Present at Upcoming ThinkEquity Partners Conference
8. Martek Announces Fourth Quarter and FY 2007 Financial Results
9. Martek Signs DHA/ARA License and Supply Agreement With IlDong Foodis for Infant Formula in South Korea
10. Leading DHA Expert and Former NIH Researcher, Dr. Norman Salem, Jr., to Join Martek as Chief Scientific Officer
11. Challenge Spreadable Butter Now Features Marteks lifesDHA(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... BETHESDA, Md. , Feb. 4, 2016  Spherix ... committed to the fostering and monetization of intellectual property, ... VTech and Uniden in the Northern District of ... are moving forward.  Inter Partes ... the U.S. Patent Office.  The IPR was initiated on ...
(Date:2/4/2016)... Brooklyn, NY (PRWEB) , ... February 04, 2016 , ... ... cuvettes for over 10 years. What sets them apart from other cuvette ... that is posted on their website. On top of this steady flow of ...
(Date:2/3/2016)... 3, 2016 Ascendis Pharma A/S (Nasdaq: ... its innovative TransCon technology to address significant unmet medical ... investor conference.Event:2016 Leerink Partners Global Healthcare Conference Location: ... February 10, 2016 Time:  , 11:55am EST ... --> An audio webcast of this event will ...
(Date:2/3/2016)... ON (PRWEB) , ... February 03, 2016 , ... ... and validating a series of potential targets (epitopes) specific to misfolded, propagating strains ... targets to create specific monoclonal antibody therapeutics for Alzheimer’s. , Following on from ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016 This ... the bioinformatic market by reviewing the recent advances ... tools that drive the field forward. Includes forecast ... Identify the challenges and opportunities that exist ... and software solution developers, as well as IT ...
(Date:2/2/2016)... 2, 2016 Technology Enhancements Accelerate Growth of X-ray ... the digital and computed radiography markets in ... Indonesia (TIM). It provides an ... as well as regional market drivers and restraints. The ... penetration and market attractiveness, both for digital and computed ...
(Date:2/2/2016)... 2016  Based on its recent analysis of ... US-based Intelligent Retinal Imaging Systems (IRIS) with the ... New Product Innovation. IRIS, a prominent cloud-based retinal ... , is poised to set the new ... market. The IRIS technology presents superior price-performance value ...
Breaking Biology News(10 mins):